The Effect of Ixazomib on the Latent HIV Reservoir
Public ClinicalTrials.gov record NCT02946047. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Pilot Study of Ixazomib to Reduce the Number of HIV DNA Positive Lymphoid Cells
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of the trial is to determine the safety and tolerability of ixazomib in HIV infected patients on antiretroviral therapy. The secondary purpose is to determine the effect of ixazomib on the size of the HIV reservoir.
Study identification
- NCT ID
- NCT02946047
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 17 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 19, 2017
- Primary completion
- Aug 18, 2019
- Completion
- Aug 18, 2019
- Last update posted
- Jan 5, 2022
2017 – 2019
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Human Immunodeficiency Virus (HIV) trials
Other public records listing Human Immunodeficiency Virus (HIV). Sorted by last update posted; newest first. Not a recommendation.
- NCT07756736: Psilocybin Therapy for Methamphetamine Use Disorder and HIV Not yet recruiting
- NCT07520188: C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States Not yet recruiting
- NCT07044297: A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) Recruiting
- NCT07466836: The Effects of Chiropractic Care on Inflammation and Quality of Life in People Living With HIV Recruiting
- NCT05657106: Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk Active, not recruiting
- NCT06598397: Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02946047, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2022 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02946047 live on ClinicalTrials.gov.